| 764008 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
496 Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.496 |
Knorr David, Ravetch Jeffrey, D’Andrea Gabriela, Vahdat Linda, Klebanoff Christopher, Robson Mark |
| 764007 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas |
2021-11-01 |
10.1136/jitc-2021-sitc2021.495 |
Wang Judy, Falchook Gerald, Nabhan Salah, Kulkarni Meghana, Sandy Peter, Dosunmu Ololade, Gardner Humphrey, Bendell Johanna, Johnson Melissa |
| 764006 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
365 Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.365 |
Schmidt Guenter, Kapil Ansh, Meinecke Lina, Sekhavati Farzad, Lesniak Jan, Shumilov Anatoliy, Padel Thomas |
| 764005 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status |
2021-11-01 |
10.1136/jitc-2021-sitc2021.364 |
Garassino Marina Chiara, Rodriguez-Abreu Delvys, Gadgeel Shirish M, Kowalski Dariusz M, Kasahara Kazuo, Felip Enriqueta, Wu Yi-Long, Castro Gilberto de, Cho Byoung Chul, Turna Hande Z, Horinouchi Hidehito, Reck Martin, Hui Rina, Garon Edward B, Boyer Michael, Mok Tony SK, Lopes Gilberto, Kobie Julie, Li Yongjin, Ayers Mark A, Cristescu Razvan, Zhao Bin, Catherine Pietanza M, Herbst Roy S |
| 764004 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.363 |
Castro Gilberto de, Kudaba Iveta, Wu Yi-Long, Lopes Gilberto, Kowalski Dariusz M, Turna Hande Z, Caglevic Christian, Zhang Li, Karaszewska Boguslawa, Laktionov Konstantin K, Srimuninnimit Vichien, Bondarenko Igor, Kubota Kaoru, Mukherjee Rinee, Lin Jianxin, Souza Fabricio, Mok Tony SK, Cho Byoung Chul |
| 764003 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
362 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.362 |
Merle Philippe, Mata Helena Verdaguer, Xie Congying, Hubner Richard, Liu Yong, Margetts Jane, Cheng Ying, Chao Yee, Fei Cong, Ling Chen, Huang Ruiqi, Wu Xikun, Shen Zhirong, Li Bai, Duque Sandra Chica, Ren Zhenggang |
| 764002 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.359 |
Pousa Antonio López, Felip Enriqueta, Forster Martin, Doger Bernard, Roxburgh Patricia, Bajaj Pawan, Peguero Julio, Carcereny Enric, Krebs Matthew, Mueller Christian, Triebel Frederic |
| 764001 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
896 Fighting the war against COVID-19: administration of bamlanivimab (BAM) or bamlanivimab + etesivimab (BAM + E); a cooperative effort between a community cancer center and an urgent care (UC) facility |
2021-11-01 |
10.1136/jitc-2021-sitc2021.896 |
Skeffington Patrick, Aisenberg Robert, Dallacosta Janice, Donaghy Ian, Hackner Dani, Houde Kelly, Moraes Kathy, Santos Annemarie |
| 764000 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
895 Discovery of a safer 4–1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging |
2021-11-01 |
10.1136/jitc-2021-sitc2021.895 |
Tsun Andy, Zhai Tianhang, Miao Xiaoniu, Huang Weifeng, Wang Chao, Xu Yifeng, Yuan Zhijun, Wang Tao, Dai Shuang, Peng Shaogang, Pang Tuling, Jiang Wenchao, Huang Yuhua, Zou Yuefeng, Xu Yingda, Sun Joanne, Gong Xinjiang, Li Bin |
| 763999 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
894 The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing |
2021-11-01 |
10.1136/jitc-2021-sitc2021.894 |
Zambarda Chiara, Guldevall Karolin, Zambarda Chiara, Guldevall Karolin, Breunig Christian, Toullec Damien, Fontana Jacopo, Pinto Sheena, Pahl Jens, Wingert Susanne, Koch Joachim, Önfelt Björn |
